Brokerages Set Bicara Therapeutics Inc. (NASDAQ:BCAX) PT at $32.40

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been given an average rating of “Moderate Buy” by the fifteen brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation, nine have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $32.6364.

A number of brokerages recently commented on BCAX. Wells Fargo & Company upped their price target on shares of Bicara Therapeutics from $16.00 to $23.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 12th. Wedbush upped their price target on shares of Bicara Therapeutics from $30.00 to $33.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Morgan Stanley raised their target price on shares of Bicara Therapeutics from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Wall Street Zen upgraded Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 24th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Bicara Therapeutics in a research report on Friday.

Bicara Therapeutics Trading Down 1.3%

NASDAQ BCAX opened at $23.58 on Tuesday. The firm’s fifty day moving average price is $26.59 and its two-hundred day moving average price is $22.17. Bicara Therapeutics has a 1 year low of $10.30 and a 1 year high of $30.99. The firm has a market capitalization of $1.56 billion, a P/E ratio of -7.61 and a beta of -0.75.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.82). On average, research analysts anticipate that Bicara Therapeutics will post -3.45 EPS for the current fiscal year.

Insider Transactions at Bicara Therapeutics

In other Bicara Therapeutics news, CFO Ivan Hyep sold 12,500 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.97, for a total transaction of $349,625.00. Following the completion of the transaction, the chief financial officer directly owned 129,855 shares in the company, valued at $3,632,044.35. The trade was a 8.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 18,750 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $27.98, for a total value of $524,625.00. Following the sale, the chief operating officer owned 181,641 shares of the company’s stock, valued at $5,082,315.18. The trade was a 9.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 108,000 shares of company stock valued at $3,079,236. Company insiders own 13.80% of the company’s stock.

Institutional Investors Weigh In On Bicara Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Bicara Therapeutics in the fourth quarter valued at approximately $45,000. Legal & General Group Plc boosted its holdings in shares of Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after acquiring an additional 1,233 shares in the last quarter. Larson Financial Group LLC grew its position in Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after acquiring an additional 3,595 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after purchasing an additional 3,866 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its stake in shares of Bicara Therapeutics by 385.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after buying an additional 4,585 shares during the period.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.